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Abstract
Background Stromal fibroblasts associated with in situ and
invasive breast carcinoma differ phenotypically from fibroblasts
associated with normal breast epithelium, and these alterations
in carcinoma-associated fibroblasts (CAF) may promote breast
carcinogenesis and cancer progression. A better understanding
of the changes that occur in fibroblasts during carcinogenesis
and their influence on epithelial cell growth and behavior could
lead to novel strategies for the prevention and treatment of
breast cancer. To this end, the effect of CAF and normal breast-
associated fibroblasts (NAF) on the growth of epithelial cells
representative of pre-neoplastic breast disease was assessed.
Methods NAF and CAF were grown with the nontumorigenic
MCF10A epithelial cells and their more transformed,
tumorigenic derivative, MCF10AT cells, in direct three-
dimensional co-cultures on basement membrane material. The
proliferation and apoptosis of MCF10A cells and MCF10AT
cells were assessed by 5-bromo-2'-deoxyuridine labeling and
TUNEL assay, respectively. Additionally, NAF and CAF were
compared for expression of insulin-like growth factor II as a
potential mediator of their effects on epithelial cell growth, by
ELISA and by quantitative, real-time PCR.
Results In relatively low numbers, both NAF and CAF
suppressed proliferation of MCF10A cells. However, only NAF
and not CAF significantly inhibited proliferation of the more
transformed MCF10AT cells. The degree of growth inhibition
varied among NAF or CAF from different individuals. In greater
numbers, NAF and CAF have less inhibitory effect on epithelial
cell growth. The rate of epithelial cell apoptosis was not affected
by NAF or CAF. Mean insulin-like growth factor II levels were not
significantly different in NAF versus CAF and did not correlate
with the fibroblast effect on epithelial cell proliferation.
Conclusion Both NAF and CAF have the ability to inhibit the
growth of pre-cancerous breast epithelial cells. NAF have
greater inhibitory capacity than CAF, suggesting that the ability
of fibroblasts to inhibit epithelial cell proliferation is lost during
breast carcinogenesis. Furthermore, as the degree of
transformation of the epithelial cells increased they became
resistant to the growth-inhibitory effects of CAF. Insulin-like
growth factor II could not be implicated as a contributor to this
differential effect of NAF and CAF on epithelial cell growth.
Keywords: breast cancer, breast epithelium, fibroblast, insulin-like growth factor, stroma
Introduction
The structure and homeostasis of normal breast paren-
chyma is maintained by dynamic interactions between
breast epithelial cells and their associated stroma. These
stromal elements include the vasculature, adipocytes, resi-
dent immune cells, and fibroblasts with their numerous cel-
lular products, including various growth factors and
extracellular matrix (ECM) components. In breast cancers,
3D = three-dimensional; BrdU = 5-bromo-2'-deoxyuridine; CAF = carcinoma-associated fibroblasts; CK = cytokeratin; DCIS = ductal carcinoma in 
situ; DMEM = Dulbecco's modified Eagle's medium; ECM = extracellular matrix; E:F = ratio of epithelial cells to fibroblasts; ELISA = enzyme-linked 
immunosorbent assay; FITC = fluorescein isothiocyanate; H&E = hematoxylin and eosin; HPLC = high-performance liquid chromatography; IGF = 
insulin-like growth factor; NAF = normal breast-associated fibroblasts; PBS = phosphate-buffered saline; PCR = polymerase chain reaction.Breast Cancer Research    Vol 7 No 1    Sadlonova et al.
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the stroma differs from stroma found in normal breast. The
stromal alterations that accompany most invasive breast
carcinomas are morphologically characterized by an
enhanced accumulation of fibroblasts and a modified, col-
lagenized extracellular matrix. Breast carcinoma-associated
fibroblasts (CAF) have been reported to express increased
amounts of specific ECM molecules, various molecules
that modulate the ECM, and several peptide growth fac-
tors, including insulin-like growth factor (IGF) II, in compar-
ison with fibroblasts in histologically normal breast (i.e.
normal breast-associated fibroblasts [NAF]) [1,2].
Fibroblasts surrounding ductal carcinoma in situ (DCIS),
prior to the development of invasive carcinoma, also differ
from those in histologically normal breast tissue. Some of
the molecular alterations found in CAF also have been doc-
umented, by immunohistochemistry and by in situ hybridi-
zation, in the fibroblasts surrounding the DCIS [3-6]. This
suggests an accumulation of alterations in stromal fibrob-
lasts (i.e. a progression from NAF to CAF) surrounding the
breast epithelium as it progresses from normal to hyperpla-
sia to DCIS and invasive cancer.
The role that these stromal changes play in the develop-
ment and progression of breast cancer and their effect on
fibroblast–epithelial cell interactions is a current topic of
much interest. It is theorized that CAF act to enhance
breast cancer progression [2], and much of the experimen-
tal evidence to date supports this contention [7-14]. How-
ever, assessment of the effect of CAF has concentrated on
established breast cancers. The focus in the present article
is on the effect of fibroblasts on the growth of epithelial
cells derived from benign breast disease, specifically prolif-
erative breast disease (i.e. MCF10A cells and MCF10AT
cells), and the potential role of fibroblast–epithelial cell
interactions to promote the development of breast cancer.
If CAF promote epithelial cell growth to a greater degree
than NAF, could preventing the alterations that occur in
fibroblasts surrounding epithelial lesions during carcino-
genesis inhibit the progression of the epithelial lesion? To
address this possibility, the key signaling and regulatory
pathways mediating the effects of fibroblast–epithelial cell
interactions, as well as the way in which these interactions
are altered during carcinogenesis, must be identified.
Studies to date indicate that the IGF system may play a role
in the stromal–epithelial interactions that affect breast can-
cer progression. IGF I and IGF II both function in cellular
growth, in differentiation, and in survival in all tissues. Sign-
aling by IGF I and IGF II through their principal receptor, the
insulin-like growth factor receptor, can promote cell cycle
progression and can inhibit apoptosis [15]. In breast can-
cer, the normal regulation and functioning of the IGF sys-
tem is altered, and the insulin-like growth factor receptor is
expressed in 39–93% of breast cancers [16]. By in situ
mRNA analysis and immunohistochemistry, IGF II expres-
sion is reported to be increased in the stromal cells within
some breast cancers in comparison with the stromal cells
adjacent to normal breast epithelium [17]. In the present
study, the effect of NAF and CAF on the growth of pre-can-
cerous breast epithelial cells was compared. To explore a
potential role for IGF II in the growth modulation of breast
epithelial cells by NAF and CAF, the level of expression of
IGF II in CAF versus that in NAF was assessed.
NAF and CAF were grown in direct contact co-cultures
with MCF10A breast epithelial cells and MCF10AT breast
epithelial cells, both of which are considered representative
of pre-invasive breast disease. MCF10A cells were derived
from benign proliferative breast disease. These cells carry
a deletion of the chromosomal locus containing p16 and
p14ARF, and amplification of MYC [18,19]. MCF10A cells
were transfected with mutated T24 H-ras to yield the
MCF10AT cells. When suspended in the basement mem-
brane material Matrigel®, the MCF10AT cells persist as
xenografts in nude mice. The cells initially form structures
that resemble normal breast epithelium, and then gradually
undergo transition to structures resembling proliferative
breast disease and DCIS. Approximately 25% of the
MCF10AT xenografts develop invasive carcinoma. The
MCF10AT model thus reflects temporally and morphologi-
cally high-risk human proliferative breast disease [20,21].
Our in vitro model consists of a three-dimensional (3D)
direct co-culture system in Matrigel® similar to that utilized
by Debnath and colleagues and by Shekhar and colleagues
[19,22]. A 3D system was selected over standard monol-
ayer cultures because it more closely simulates in vivo
growth [19]. When grown in Matrigel®, human luminal
breast epithelial cells, primary or immortalized, form spheri-
cal polarized structures that resemble normal lobular acini.
This spatial organization of cells determines how cells per-
ceive and respond to signals from the stromal microenvi-
ronment [23].
Importantly, it has been demonstrated that intracellular sig-
naling directing the proliferation of breast epithelial cells dif-
fers in cells grown in two dimensions versus those grown
in three dimensions [23-25]. Incorporation of NAF and CAF
in this 3D culture system allowed assessment of soluble
and insoluble secreted factors and of direct contact factors
in the fibroblast–epithelial interactions influencing epithelial
cell growth.
Methods
Maintenance of epithelial cell lines
MCF10A cells (American Type Culture Collection, Manas-
sas, VA, USA) and MCF10AT cells (Karmanos Cancer
Institute, Detroit, MI, USA) were cultivated in DMEM/Ham's
F-12 (Cambrex, Walkersville, MD, USA) supplementedAvailable online http://breast-cancer-research.com/content/7/1/R46
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with 0.1 µg/ml cholera toxin (Calbiochem, San Diego, CA,
USA), 10 µg/ml insulin (Sigma, St Louis, MO, USA), 0.5
µg/ml hydrocortisone (Sigma), 0.02 µg/ml epidermal
growth factor (Upstate Biotechnology, Lake Placid, NY,
USA) and 5% horse serum (Invitrogen, Carlsbad, CA,
USA). Subconfluent cultures (80–90% confluence) were
utilized in experiments.
Isolation, characterization and maintenance of 
fibroblast cultures
Fibroblasts were derived from mammary reduction speci-
mens (NAF) and from primary breast cancers (CAF). The
tissues were remnants of diagnostic surgical specimens
and were obtained from The University of Alabama at Bir-
mingham Tissue Procurement Facility after Institutional
Review Board approval. H&E-stained, frozen histologic
sections were prepared from each tissue sample to confirm
benignity or malignancy. The tissue samples from the
breast reduction specimens consisted predominantly of
adipose tissue, but interspersed fibrous areas were
selected for fibroblast isolation. The tissue was minced and
digested for 18–24 hours at 37°C in DMEM (Vitacell, Man-
assas, VA, USA) with 10% fetal bovine serum (Invitrogen)
supplemented with 100 U/ml streptomycin, 100 µg/ml
penicillin, 2.5 µg/ml Fungizone (GibcoBRL, Life Technolo-
gies, Grand Island, NY, USA), 150 U/ml hyaluronidase
(Sigma) and 200 U/ml collagenase type III (GibcoBRL).
The digested tissue was centrifuged at 100 relative centrif-
ugal force and plated in T25 tissue culture flasks with
DMEM and 10% fetal bovine serum. Differential trypsiniza-
tion was applied during subculturing to select for the
growth of fibroblasts [26].
Early passages (below passage 9) of all fibroblasts were
subjected to immunocytochemical evaluation with anti-
vimentin (mouse IgG1, clone V9; Neomarkers, Fremont,
CA, USA), anti-epithelial membrane antigen (mouse IgG2a,
clone ZCE113; Zymed, San Francisco, CA, USA), and anti-
cytokeratin (CK) 5/CK 8 (mouse IgG1, clone C-50; Neo-
markers) as confirmation of their stromal origin (i.e. strong
vimentin expression, and absence of epithelial membrane
antigen and CK 5/CK 8). Epithelial membrane antigen and
CK 8 are expressed primarily in luminal breast epithelial
cells, whereas CK 5 is found in myoepithelial cells [27]. For
immunocytochemical evaluation, fibroblasts were grown on
glass coverslips, fixed in 70% ethanol and were permeabi-
lized with acetone. Fibroblasts were incubated in 3%
hydrogen peroxide followed by 3% goat serum at room
temperature. Anti-vimentin (0.5 µg/ml), anti-epithelial mem-
brane antigen (1 µg/ml), or anti-CK 5/CK 8 (0.3 µg/ml)
were applied for 1 hour at room temperature. Secondary
detection was accomplished with a streptavidin/horserad-
ish peroxidase secondary detection system (Signet Labo-
ratories, Dedham, MA, USA) and diaminobenzidine
(BioGenex, San Ramon, CA, USA). Harris hematoxylin was
used as a counterstain.
The fibroblasts were routinely maintained in DMEM and
10% fetal bovine serum. Subconfluent cultures (70–90%
confluence) of lower passages (below passage 9) were uti-
lized for the experiments described. Only early-passage
fibroblast cultures are used in experiments to more closely
simulate their in vivo phenotype. It has been shown that
early-passage (below passage 9) colonic primary fibrob-
lasts maintain many of their in vivo characteristics, includ-
ing expression of alpha-smooth muscle actin, collagen IV
and laminin 1 [28]. Multiple NAF and CAF cultures were uti-
lized because of potential variation among fibroblasts from
different individuals and different breast cancers.
Preparation of the 3D cultures
The effect of NAF and CAF on MCF10A breast epithelial
cells and MCF10AT breast epithelial cells was studied
using a 3D in vitro model. In co-cultures, epithelial cells and
fibroblasts were mixed in Human Endothelial–SFM Basal
Growth Media (Invitrogen) supplemented with 10 ng/ml
epidermal growth factor and 20 ng/ml basic fibroblast
growth factor (Invitrogen). This was followed by dispersal
on 100 µl basement membrane material (Growth Factor
Reduced Matrigel®; BD Biosciences, Bedford, MA, USA)
in each well of eight-well chamber slides (Lab-Tek® Cham-
ber Slide™ System; Nalge Nunc International, Naperville, IL,
USA).
The ratio of epithelial cells to fibroblasts (E:F) ranged from
2:1 to 1:3 by varying the number of fibroblasts while keep-
ing the number of epithelial cells constant (100,000 cells/
well). Controls consisted of 3D monocultures of MCF10A
cells and MCF10AT cells (100,000 cells/well). All cultures
were incubated in a 37°C, 5% CO2 humidified incubator for
14 days with supplementation of fresh Human Endothelial-
SFM Basal Growth Media supplemented with 10 ng/ml
epidermal growth factor and 20 ng/ml basic fibroblast
growth factor at 4-day intervals.
Morphologic development was observed by phase contrast
microscopy. 5-bromo-2'-deoxyuridine (BrdU) (0.2 mg/ml;
Calbiochem) was applied to all cultures for 24 hours. The
cultures were removed from the chamber slides, were
embedded in HistoGel specimen processing gel (Richard-
Allan, Kalamazoo, MI, USA), were fixed in 10% neutral-buff-
ered formalin, and were embedded in paraffin. Histologic
sections were prepared for H&E staining and
immunocytochemistry.
BrdU detection by immunocytochemistry
Distinction of epithelial cells from fibroblasts in the 3D cul-
tures was accomplished by examination of the cell mor-
phology and location within the culture. To ensure that onlyBreast Cancer Research    Vol 7 No 1    Sadlonova et al.
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epithelial cells were counted, however, immunostaining
with anti-BrdU (mouse IgG1, clone Bu20a; DAKO, Carpin-
teria, CA, USA) was followed by immunostaining with anti-
C K  5 / C K  8 ,  e x p r e s s e d  o n l y  i n  M C F 1 0 A  c e l l s  a n d
MCF10AT cells in 3D cultures. The staining entailed pre-
treatment with low-temperature antigen retrieval (i.e. incu-
bation in 0.01 M citric acid monohydrate, pH 6.0, for 2
hours in an 80°C water bath), followed by sequential incu-
bation in 1 N HCl, 3% hydrogen peroxide, 1% goat serum,
and anti-BrdU (3 µg/ml). Secondary detection was as pre-
viously described. This was followed by incubation with
anti-CK 5/CK 8 (4 µg/ml) and secondary detection using a
streptavidin/alkaline phosphatase reagent (Signet Labora-
tories) and New Fuchsin (BioGenex) as the chromogen.
The slides were lightly counterstained with Harris
hematoxylin.
The resulting dual coloration of anti-BrdU (brown nucleus)
and anti-CK 5/CK 8 (pink cytoplasm) enabled identification
of proliferating epithelial cells. A BrdU-labeling index in the
epithelial cells was determined by calculating the percent-
age of epithelial cells with nuclear staining for anti-BrdU in
complete cross-sections of the 3D cultures. A minimum of
500 epithelial cells was counted. Negative controls con-
sisted of histologic sections of each 3D culture processed
without the addition of primary antibodies.
BrdU detection by flow cytometry
Cells were gently removed from 3D cultures after treatment
with Dispase (BD Biosciences Discovery Labware, Bed-
ford, MA, USA), followed by 5–10 mM EDTA. Recovered
cells were washed with cold PBS. To distinguish co-cul-
tured epithelial cells from fibroblasts, allophycocyanin-con-
jugated anti-EpCAM (mouse IgG1, clone EBA-1; BD
Biosciences Immunocytometry Systems, San Jose, CA,
USA) was used to label MCF10A cells and MCF10AT
cells. The cells were permeabilized and fixed (BD Cytofix/
Cytoperm and Perm/Wash kit; BD Biosciences Pharmin-
gen, San Diego, CA, USA). Prior to staining with FITC-con-
jugated anti-BrdU (mouse IgG1, clone B44; BD
Biosciences Immunocytometry Systems), cells were
treated with DNase I (Roche Diagnostics GmbH, Penz-
berg, Germany). Samples were analyzed on a BD FACS
Calibur™ flow cytometer (BD Biosciences). The percent-
age of BrdU-labeled epithelial cells (positive for anti-
EpCAM and anti-BrdU) was calculated from the total
acquired events.
Assessment of apoptosis by TUNEL assay
Apoptosis was quantified in epithelial cells in 3D cultures
by the TUNEL Assay (ApopTag Peroxidase In Situ Apopto-
sis Kit; Integren Co., Purchase, NY, USA) as per the manu-
facturer's instructions. In the TUNEL assay, terminal
deoxynucleotide transferase was used to label fragmented
DNA with digoxigenin-linked nucleotides. These nucle-
otides were then detected using an anti-digoxigenin anti-
body. Negative controls consisted of histologic sections of
each 3D culture processed without the addition of terminal
deoxynucleotide transferase. Sequential sections of each
3D culture were stained with anti-CK 5/CK 8, as previously
described, and were used to aid in identification of epithe-
lial cells in co-cultures. The percentage of epithelial cells
with nuclear staining was determined in complete cross-
sections of the 3D cultures. A minimum of 500 epithelial
cells was counted.
Preparation of cell lysates
Cells were gently removed from Matrigel® in 3D co-cultures
of MCF10AT cells (100,000 cells/well) with fibroblasts
(50,000 cells/well) and monocultures of MCF10AT cells
(100,000 cells/well) or fibroblasts (50,000 cells/well)
using dispase, as previously described. The released cells
were washed with cold PBS to remove residual Matrigel®.
Cell lysates were prepared from 3D cultures and monolayer
cultures with NEB lysis buffer (Cell Signaling Technology,
Beverly, MA, USA) containing 20 mM Tris–HCl (pH 7.5),
150 mM NaCl, 1 mM Na2EDTA, 1 mM EGTA, 1% Triton,
2.5 mM sodium pyrophosphate, 1 mM β-glycerophos-
phate, 1 mM Na3VO4, 1 µg/ml leupeptin, 10 mM sodium
fluoride, a Complete Mini Protease Inhibitor Cocktail tablet
(Roche, Indianapolis, IN, USA) and 1 mM phenylmethylsul-
fonylfluoride, and were cleared by centrifugation. All lysates
were concentrated with Millipore Microcon® Centrifugal Fil-
ter Devices YM-3 (Millipore Corporation, Bedford, MA,
USA). The protein concentration of lysates was measured
with the BCA Protein Assay Kit (Pierce, Rockford, IL, USA).
Enzyme-linked immunosorbent assay
The protein levels of IGF II in cell lysates were measured by
ELISA for human IGF II (DSL-10-9100 Active™ IGF-II
ELISA; Diagnostic System Laboratories, Webster, TX,
USA) as per the manufacturer's instructions. The kit
includes a modified version of the standard acid–ethanol
extraction prior to ELISA. The ELISA for IGF II shows no
detectable cross-reactivity with IGF I, insulin, IGF binding
protein 1, and IGF binding protein 3. The minimum detec-
tion limit of the assay is 0.25 ng/ml. The amount of IGF II
present in lysates from cell lines and 3D cultures was nor-
malized to the total protein concentration.
Quantitative real-time PCR
RNA isolation (Trizol reagent; GibcoBRL) was followed by
RNA clean-up with RNeasy columns (Qiagen, Valencia,
CA, USA). Spectrophotometric ratios of A260 to A280 were
greater than 1.8. The forward, reverse and probe oligonu-
cleotides were synthesized and purified by HPLC (Applied
Biosystems, Foster City, CA, USA) after complete evalua-
tion of the IGF II and ribosomal S9 gene sequences (Gen-
Bank database) (IGF II forward, 5'-
GTCGATGCTGGTGCTTCTCA-3' and reverse, 5'-Available online http://breast-cancer-research.com/content/7/1/R46
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GGGCGGTAAGCAGCAATG-3' ; probe, 5'-
6FAMCTTCTTGGCCTTCGCCTCGTGCTTAMRA-3' ;
ribosomal S9 forward, 5'-ATCCGCCAGCGCCATA-3'
and reverse, 5'-TCAATGTGCTTCTGGGAATCC-3' ;
probe, 5'-
6FAMAGCAGGTGGTGAACATCCCGTCCTTTAMRA-
3') using the Primer Express software (Applied
Biosystems).
Fluorescent signal data were collected by the ABI Prism
7700 Sequence Detection System (Applied Biosystems).
The log-linear phase of amplification was monitored to
obtain the threshold cycle (defined as the fractional cycle
number at which the amount of the amplified target reaches
a fixed threshold) values for each RNA sample. Ribosomal
S9 was used as the internal reference and was selected
because it exhibits minimal variability in tissues of different
origins [29]. The comparative threshold cycle method was
employed to determine IGF II expression levels in each
sample relative to a calibrator, in this case MCF10AT cells
[29,30]. Each sample was run in triplicate.
Statistical analysis
A relationship between BrdU labeling or apoptotic indexes
and co-culture with NAF or with CAF was assessed by mul-
tiple linear regression analysis to allow combining replicate
experiments performed on different days. Results of ELISA
and quantitative real-time PCR were compared by t test.
Outliers were eliminated prior to analysis using a basic out-
lier test, where a high outlier was defined as a number
greater than quartile 3 + 1.5 (interquartile range) and a low
outlier was less than quartile 1 – 1.5 (interquartile range).
Results
Fibroblasts alter the 3D morphology of MCF10A cells 
and MCF10AT cells
The immunocytochemical characterization of fibroblasts
used in the described experiments confirmed their stromal
nature. Immunostaining for vimentin was strongly positive
and staining for epithelial membrane antigen and CK 5/CK
8 was negative.
In 3D monocultures, both MCF10A cells and MCF10AT
cells initially form a lattice-like network of duct-like struc-
tures. After several days, the lattice-like network is replaced
by a predominance of rounded epithelial cell groups (sphe-
roids) (Fig. 1a,1b,1c,1d). MCF10A cells form small,
rounded spheroids (Figs 1b and 2a). MCF10AT cells
aggregate into larger solid groups or sheets with extensive
squamous metaplasia (Figs 1d and 2c). The formation of
larger three-dimensional structures and the abnormal differ-
entiation (i.e. squamous metaplasia) of MCF10AT cells
supports their greater degree of transformation.
In 3D co-cultures with NAF or with CAF, the epithelial cells
and fibroblasts form large rounded structures (Fig. 1e). In
histologic sections of co-cultures with NAF or with CAF,
MCF10A cells and MCF10AT cells form spheroids or
sheets within Matrigel®, as seen in monocultures, and
these epithelial groups surround an aggregate of fibrob-
lasts (Fig. 2b,2d). These 3D co-cultures resemble a termi-
nal duct-lobular unit in the normal breast or in proliferative
breast disease/DCIS (Fig. 3a,3b,3c), in that epithelial cells
are arranged in groups (similar to an acinus or a terminal
duct) surrounded by a laminin-rich basement membrane
with fibroblasts located outside the basement membrane
and separating epithelial groups. The 3D in vitro model dif-
fers from normal breast or in situ breast disease in vivo,
Figure 1
MCF10A cells and MCF10AT cells in monoculture and in co-culture  with fibroblasts MCF10A cells and MCF10AT cells in monoculture and in co-culture 
with fibroblasts. (a), (b) MCF10A cells and (c), (d) MCF10AT cells in 
monoculture initially form a lattice/scaffold arrangement (a, c). After sev-
eral days of culture, spheroidal structures become more prominent (b, 
d). (e) MCF10AT cells in co-culture with fibroblasts form three-dimen-
sional rounded structures. Similar structures are formed by MCF10A 
cells in co-culture with fibroblasts (phase contrast, 100 × magnifica-
tion; scale bar, 200 µm).Breast Cancer Research    Vol 7 No 1    Sadlonova et al.
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however, in that the number of fibroblasts centrally located
and between epithelial cell groups is greater than that typ-
ically seen in vivo. Additionally, the fibroblasts in the in vitro
model are surrounded by an ECM rich in laminin and colla-
gen IV [31], whereas in vivo collagen I would typically pre-
dominate [32].
In 3D co-cultures, both NAF and CAF markedly sup-
pressed squamous metaplasia of MCF10AT cells as
observed on H&E-stained sections of monocultures,
thereby normalizing the morphology to a glandular pheno-
type (Fig. 2c,2d). No obvious differences between NAF
and CAF in morphology, growth pattern or adhesion to sub-
strate, in either a monolayer or the 3D culture, were
observed.
NAF and CAF affect the rate of proliferation of MCF10A 
cells and MCF10AT cells in 3D co-culture
In replicate co-cultures of MCF10A cells with three differ-
ent NAF and CAF grown in an E:F of 2:1, both types of
fibroblasts significantly reduced proliferation of MCF10A
cells. The mean BrdU-labeling index of MCF10A cells,
when measured by immunocytochemistry, was decreased
by 47% in co-culture with NAF (n = 19, P = 0.009) and by
39% in co-culture with CAF (n = 19, P = 0.024) relative to
the MCF10A monoculture (Table 1 and Fig. 4). The BrdU-
labeling index of MCF10AT cells was reduced by 49% in
the presence of NAF (n = 20, P = 0.013), relative to the
MCF10AT monoculture, whereas co-culture with CAF
failed to significantly lower the MCF10AT BrdU-labeling
Figure 2
H&E-stained histologic sections of MCF10A cell and MCF10AT cell  monocultures and co-cultures with fibroblasts H&E-stained histologic sections of MCF10A cell and MCF10AT cell 
monocultures and co-cultures with fibroblasts. (a) MCF10A cells form 
small spheroids. (b) MCF10A cells in co-culture with fibroblasts are 
located adjacent to the fibroblast aggregate (F) and maintain smaller 
spheroids. (c) In monoculture, MCF10AT cells form larger rounded 
three-dimensional structures. (d) In co-culture, MCF10AT cells form 
solid sheets and rounded groups of cells located adjacent to the fibrob-
lasts (F). The occurrence of squamous metaplasia (SM) is more evident 
in MCF10AT monocultures, while it is suppressed in co-cultures. Over-
all, MCF10A cells have less squamous metaplasia than MCF10AT cul-
tures (400 × magnification; scale bar, 50 µm).
Figure 3
Distribution and relative quantities of fibroblasts and epithelial cells in a  normal terminal duct-lobular unit, hyperplasia and ductal carcinoma in  situ (DCIS) Distribution and relative quantities of fibroblasts and epithelial cells in a 
normal terminal duct-lobular unit, hyperplasia and ductal carcinoma in 
situ (DCIS). (a) A terminal duct-lobular unit with epithelial cells (arrow-
heads) arranged in acini and intralobular terminal ducts separated by 
stroma-containing fibroblasts (arrows) in a ratio of epithelial cells to 
fibroblasts (E:F) of 2.7:1. (b) Ductal hyperplasia with a proliferation of 
epithelial cells (arrowheads) filling and expanding terminal ducts sepa-
rated by reactive stroma including fibroblasts (arrows) in an E:F of 
3.3:1. (c) High-grade DCIS, with epithelial cells (arrowheads) demon-
strating markedly atypical nuclei, involving terminal ducts separated by 
reactive stroma including fibroblasts (arrows) in an E:F of 2:1 (200 × 
magnification; scale bar, 50 µm).Available online http://breast-cancer-research.com/content/7/1/R46
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index (n = 22, P = 0.935) (Table 2 and Fig. 4). The effect
of NAF versus CAF on the rate of proliferation of MCF10AT
cells was significantly different (P < 0.001). The effect was
further confirmed by repeating the co-cultures to measure
the BrdU-labeling index by flow cytometry, rather than by
immunocytochemistry (Fig. 5).
There was variability among NAF cultures and among CAF
cultures in their ability to suppress proliferation of MCF10A
cells and MCF10AT cells (Tables 1 and 2) in this 3D cul-
ture system, potentially reflecting heterogeneity among the
individuals from which the fibroblasts were derived.
Because of this variability, detection of a significant differ-
ence in the function of NAF and CAF required many repli-
cates and multiple fibroblast cultures derived from different
individuals.
In a prior report, CAF was found to promote, rather than
inhibit, the growth of MCF10A cells in a similar 3D co-cul-
ture system [22]. One of several possible explanations for
this discrepancy between the prior result and the present
result is a difference in E:F. Shekhar and colleagues used
an E:F of 1:1 rather than the E:F of 2:1 we initially used
[22]. The number of fibroblasts has been shown to have an
effect on the response of epithelial cells [7,9,14]. We
therefore repeated the 3D co-cultures of MCF10A cells
using NAF-2 and CAF-1 with increasing numbers of fibrob-
lasts (i.e. a decreasing E:F) (Fig. 6). BrdU labeling was
assessed by immunocytochemistry of histologic sections
of 3D cultures.
As previously, NAF-2 at an E:F of 2:1 suppressed prolifer-
ation of MCF10A cells. However, with increasing numbers
of NAF-2, this suppression effect was gradually weakened
(P = 0.043). Although we found no significant difference in
the suppressive effect of NAF-2 in an E:F of 2:1 versus an
E:F of 1:1 or of 1:2, there was a significantly greater rate of
proliferation of MCF10A cells with NAF-2 in an E:F of 1:3
compared with in an E:F of 2:1 (P = 0.028). More impor-
tantly, CAF-1 at an E:F of 1:1 did not significantly suppress
proliferation, whereas our original ratio of 2:1 did (P  =
0.025). CAF-1 at an E:F of 1:2 also conferred a higher rate
of proliferation of MCF10A cells than the E:F of 2:1, but this
did not reach statistical significance (P = 0.054). At an E:F
Table 1
5-Bromo-2'-deoxyuridine (BrdU) labeling* of MCF10A cells grown in monoculture (control group) and in co-cultures with normal 
breast-associated fibroblasts (NAF) and carcinoma-associated fibroblasts (CAF)
Culture BrdU-labeling indices of 
MCF10A cells (mean ± 
standard error of the mean)
BrdU-labeling indices of 
MCF10A cells (group mean ± 
standard error of the mean)
Comparison of BrdU-labeling indices of MCF10A cells between 
groups (linear regression)
MCF10A (n = 6) 30.3 ± 3.0 30.3 ± 3.0 MCF10A vs MCF10A + NAF (P 
= 0.009)
MCF10A + NAF vs MCF10A + 
CAF (P = 0.501)
NAF-1 + MCF10A (n = 7) 21.9 ± 4.2 16.1 ± 2.6 (n = 19)
NAF-2 + MCF10A (n = 6) 10.7 ± 3.6
NAF-3 + MCF10A (n = 6) 14.7 ± 5.0
CAF-1 + MCF10A (n = 8) 15.2 ± 2.0 18.5 ± 2.5 (n = 19) MCF10A vs MCF10A + CAF (P 
= 0.024)
CAF-2 + MCF10A (n = 6) 15.5 ± 4.2
CAF-3 + MCF10A (n = 5) 27.6 ± 6.7
*Assessed by immunocytochemistry
Figure 4
Proliferation of MCF10A cells and MCF10AT cells grown in monocul- ture and co-culture with fibroblasts Proliferation of MCF10A cells and MCF10AT cells grown in monocul-
ture and co-culture with fibroblasts. The rate of proliferation of MCF10A 
cells and MCF10AT cells, as measured by the 5-bromo-2'-deoxyuridine 
(BrdU) labeling index (assessed by immunocytochemistry), was signifi-
cantly reduced in co-cultures of MCF10A cells with both normal breast-
associated fibroblasts (NAF) (P = 0.009) and carcinoma-associated 
fibroblasts (CAF) (P = 0.024) compared with the MCF10A monocul-
ture (control). The rate of proliferation of MCF10AT cells was signifi-
cantly suppressed by NAF (P = 0.013) but not by CAF (P = 0. 935) in 
comparison with the MCF10AT monoculture (control).Breast Cancer Research    Vol 7 No 1    Sadlonova et al.
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of 1:3, however, CAF-1 caused a decrease in proliferation
of MCF10A cells and enhanced cell death, as assessed by
microscopic morphology. At an E:F of 1:3, the total number
of viable MCF10A cells was reduced in co-culture with
both NAF-2 and CAF-1; however, this reduction was more
marked with CAF-1.
Neither NAF nor CAF had a significant effect on the rate of
apoptosis of MCF10A cells or MCF10AT cells when grown
at an E:F of 2:1 after 2 weeks of co-culture, as assessed by
TUNEL assay (Fig. 7).
Quantities of IGF II are no different in NAF versus CAF
As an initial attempt to identify differences between NAF
and CAF that explain our observed results, expression of
IGF II in NAF and in CAF was assessed. A higher level of
expression of IGF II in CAF than in NAF may provide an
explanation for the higher rate of proliferation of MCF10AT
cells allowed by CAF in comparison with NAF.
ELISA performed on cell lysates of NAF and CAF cultures
demonstrated variability in expression of IGF II among cul-
tures, but no significant difference was observed in the
mean IGF II quantity between NAF and CAF in monolayer
cultures (Table 3) or in 3D monocultures (Table 4).
Although in monolayer cultures more CAF than NAF had
Table 2
5-Bromo-2'-deoxyuridine (BrdU) labeling* of MCF10AT cells grown in monoculture and in co-cultures with normal breast-associated 
fibroblasts (NAF) and carcinoma-associated fibroblasts (CAF)
Culture BrdU-labeling indices of 
MCF10AT cells (mean ± 
standard error of the mean)
BrdU-labeling indices of 
MCF10AT cells (group mean 
± standard error of the mean)
Comparison of BrdU-labeling indices of MCF10AT cells between 
groups (linear regression)
MCF10AT (n = 6) 27.7 ± 7.2 27.7 ± 7.2 MCF10AT vs MCF10AT + 
NAF (P = 0.013)
MCF10AT + NAF vs MCF10AT + 
CAF (P < 0.001)
NAF-1+ MCF10AT (n = 7) 17.1 ± 2.8 14.1 ± 1.4 (n = 20)
NAF-2 + MCF10AT (n = 6) 13.8 ± 1.9
NAF-3 + MCF10AT (n = 7) 11.4 ± 1.9
CAF-1 + MCF10AT (n = 8) 25.9 ± 4.9 25.5 ± 2.8 (n = 22) MCF10AT vs MCF10AT + 
CAF (P = 0.935)
CAF-2 + MCF10AT (n = 8) 26.6 ± 3.2
CAF-3 + MCF10AT (n = 6) 23.5 ± 7.4
*Assessed by immunocytochemistry
Figure 5
5-Bromo-2'-deoxyuridine (BrdU) labeling, assessed by flow cytometry,  of MCF10AT monocultures and co-cultures with normal breast-associ- ated fibroblasts (NAF) and carcinoma-associated fibroblasts (CAF) 5-Bromo-2'-deoxyuridine (BrdU) labeling, assessed by flow cytometry, 
of MCF10AT monocultures and co-cultures with normal breast-associ-
ated fibroblasts (NAF) and carcinoma-associated fibroblasts (CAF). 
These data are representative of replicate experiments indicating that 
NAF suppress proliferation of MCF10AT cells to a greater extent than 
do CAF. Again some variability in extent of suppression is present 
among individual NAF cultures and individual CAF cultures.
Figure 6
Relative 5-bromo-2'-deoxyuridine (BrdU) indices of MCF10A cells in  co-culture with varying quantities of normal breast-associated fibroblast  NAF-2 and carcinoma-associated fibroblast CAF-1 Relative 5-bromo-2'-deoxyuridine (BrdU) indices of MCF10A cells in 
co-culture with varying quantities of normal breast-associated fibroblast 
NAF-2 and carcinoma-associated fibroblast CAF-1. With increasing 
numbers of NAF-2, the mean rate of proliferation of co-cultured 
MCF10A cells increased, with a significant difference in BrdU-labeling 
index observed between a ratio of epithelial cells to fibroblasts (E:F) of 
2:1 versus an E:F of 1:3 (P < 0.05). With increasing numbers of CAF-
1, the mean rate of proliferation was highest at an E:F of 1:1. The rate of 
proliferation at an E:F of 1:1 was significantly higher than that at an E:F 
of 2:1 (P < 0.05). At an E:F of 1:3, CAF-1 caused a decreased prolifer-
ation of and enhanced cell death of MCF10A cells.Available online http://breast-cancer-research.com/content/7/1/R46
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Table 3
Insulin-like growth factor (IGF) II ELISA for normal breast-associated fibroblasts (NAF), carcinoma-associated fibroblasts (CAF), 
MCF10A cells and MCF10AT cells in monolayer cultures
Cell type IGF II level (normalized to total protein)
Level (ng/µg) Mean (ng/µg)
NAF
NAF-1 11.63
NAF-2 6.87
NAF-3 10.31
NAF-4 7.21
NAF-5 2.92 7.79
CAF
CAF-1 11.80
CAF-2 10.58
CAF-3 10.59
CAF-4 11.27
CAF-5 10.21
CAF-6 14.07 11.42
Breast epithelial cells
MCF10A 5.56
MCF10AT 4.17 4.87
Table 4
Insulin-like growth factor (IGF) II ELISA for normal breast-associated fibroblasts (NAF), carcinoma-associated fibroblasts (CAF) and 
MCF10AT cell monocultures and co-cultures in a three-dimensional in vitro model
Cell type IGF II level (normalized to total protein)
Monoculture Co-culture with MCF10AT cells
Level (ng/µg) Mean (ng/µg) Level (ng/µg) Mean (ng/µg)
NAF
NAF-1 49.25 9.68
NAF-2 45.00 10.22
NAF-3 68.14 54.13 10.27 10.06
CAF
CAF-1 70.64 10.01
CAF-2 52.37 10.88
CAF-3 52.96 58.65 9.96 10.28
Breast epithelial cells
MCF10AT 9.98Breast Cancer Research    Vol 7 No 1    Sadlonova et al.
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IGF II levels > 10 ng/µg protein, the mean levels of IGF II
were similar (NAF versus CAF, P > 0.05) (Table 3). This
comparison included five different NAF cultures and six dif-
ferent CAF cultures. ELISA was also performed on NAF-
conditioned media and CAF-conditioned media but,
despite the concentration of samples, the levels were too
low for reliable quantification by ELISA (data not shown).
Additionally, because IGF II mRNA was previously reported
to be expressed at a higher level in CAF than in NAF, IGF II
mRNA was assessed by quantitative real-time PCR in mon-
olayer cultures of NAF and CAF. The relative expression
levels for each fibroblast culture are provided in Fig. 8.
Although more CAF cultures than NAF cultures expressed
IGF II mRNA at relatively high levels, the mean relative
expression level of IGF II mRNA for NAF (4.2, n = 5) and
for CAF (7.7, n = 5) did not differ significantly (P = 0.390).
Co-culture of MCF10A cells or MCF10AT cells may
enhance expression of IGF II in fibroblasts, as has been
reported in fibroblasts co-cultured with MCF-7 cells [33].
Furthermore, expression of IGF II may be enhanced to a
greater degree in CAF versus NAF, thus possibly explaining
the greater rate of proliferation of MCF10AT cells in co-cul-
ture with CAF than with NAF. 3D culture of NAF and CAF
also could alter expression of IGF II in comparison of the
monolayer culture. To investigate these possibilities, IGF II
levels were assessed by ELISA in 3D monocultures of the
same three NAF cultures and three CAF cultures used in
previous co-cultures, in 3D monocultures of MCF10AT
cells, and in 3D co-cultures of MCF10AT cells with NAF
and CAF in an E:F of 2:1, identical to those co-cultures
assessed for BrdU labeling previously (Table 4). In the 3D
cultures, fibroblasts expressed IGF II at a significantly
higher level than the epithelial cells (P < 0.01), and there
was no difference in IGF II between NAF and CAF (P >
0.05). In co-cultures, the overall expression of IGF II was
lower than in fibroblast monocultures. This latter result is
expected because of the addition of a relatively large
number of MCF10AT cells (E:F of 2:1) that express IGF II
at a lower level than fibroblasts. Furthermore, there was no
difference in mean IGF II levels in co-cultures with NAF ver-
sus CAF. The IGF II levels in 3D cultures were generally
higher than in monolayer cultures, and this was particularly
true when comparing 3D monocultures of fibroblasts
versus two-dimensional monocultures of fibroblasts. The
potential reasons for this include an effect of 3D growth, or
the presence of Growth Factor Reduced Matrigel® on the
expression of IGF II, and/or deviations between the ELISA
runs.
When the protein levels of IGF II in 3D monocultures of
fibroblasts or in 3D co-cultures were correlated with the
rate of proliferation of MCF10AT cells in co-culture with the
matching NAF or CAF, no significant correlation was
observed (r = 0.030 or r = 0.258, respectively; P > 0.05,
Pearson Product Moment Correlation).
Discussion
Our results indicate that both NAF and CAF have the ability
to inhibit epithelial cell proliferation and to induce glandular
differentiation to a more normal phenotype. However, CAF
have less inhibitory capacity than NAF. At relatively low
concentrations of fibroblasts (E:F of 2:1) NAF can sup-
press proliferation of both MCF10A cells and MCF10AT
cells, whereas CAF can suppress proliferation of MCF10A
cells but not the more transformed MCF10AT cells. In vivo
NAF may thus have an inhibitory and regulatory effect on
Figure 7
TUNEL assay for MCF10A cells and MCF10AT cells in co-culture with  normal breast-associated fibroblasts (NAF) and carcinoma-associated  fibroblasts (CAF) TUNEL assay for MCF10A cells and MCF10AT cells in co-culture with 
normal breast-associated fibroblasts (NAF) and carcinoma-associated 
fibroblasts (CAF). Co-culture with NAF and CAF had no significant 
effect on the rate of apoptosis of MCF10A cells and MCF10AT cells in 
comparison with epithelial cell monoculture controls.
Figure 8
Comparative expression of insulin-like growth factor (IGF) II mRNA Comparative expression of insulin-like growth factor (IGF) II mRNA. IGF 
II expression levels in MCF10A cells, MCF10AT cells, normal breast-
associated fibroblasts (NAF) and carcinoma-associated fibroblasts 
(CAF) were determined by quantitative real-time PCR. All expression 
levels are relative to the calibrator, MCF10AT cells. The error bars rep-
resent the standard deviation of triplicate assays for each sample. Com-
parison of the mean expression level between NAF (mean = 4.2) and 
CAF (mean = 7.7) did not reach statistical significance (P = 0.39, t 
test).Available online http://breast-cancer-research.com/content/7/1/R46
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the proliferation of normal epithelial cells. This suppressive
ability may be lost or reduced as epithelial lesions gradually
progress from hyperplasia to DCIS and invasive cancer,
and correspondingly NAF become CAF.
Differences in gene expression between CAF and NAF
have been documented by examination of human breast
cancers by immunohistochemistry and in situ hybridization,
and also by analysis of cultures of fibroblasts isolated from
breast cancers. These documented characteristics of
breast-derived CAF are thoroughly reviewed by Kunz-
Schughart and Knuechel [1,2], and include an increased
expression of several growth factors [3,34], of ECM mole-
cules [35-37], and of proteases and protease inhibitors
involved in modulating the ECM [5,6]. Many of these differ-
ences in the expression profile of CAF in comparison with
NAF have the potential to enhance the development,
growth and progression of breast carcinoma [1]. Further-
more, a subset of the phenotypic alterations documented in
CAF have been identified in fibroblasts surrounding DCIS
by examining these lesions using immunohistochemistry or
in situ hybridization [3-6]. However, many of the changes
observed in CAF have not yet been examined in DCIS, and
it is therefore quite possible that fibroblasts surrounding
DCIS share more features with CAF than are currently
documented.
Attempts to actually demonstrate a promotional effect of
CAF on the growth of epithelial cell lines derived from
breast cancer are limited in number and have met with
somewhat conflicting results. A variety of different methods
were used in these studies, complicating comparison
among them. In most in vitro analyses, however, direct and
indirect co-culture with CAF increased the growth of MCF-
7 breast cancer cells compared with MCF-7 cells alone
[7,12,14,38]. Co-culture of NAF with MCF-7 cells caused
both growth promotion [7,10,11,13,39,40] and inhibition
[8] of MCF-7 cells. In contrast, co-culture of NAF and CAF
with the breast cancer cell line MDA-MB-231 had no
significant effect on epithelial cell growth [10,11]. In vivo,
NAF and CAF increased growth of the MCF-7 xenografts
or NAF had no effect [7,38]. Only a few reports have
addressed the effects of fibroblast–epithelial interactions
on the growth of nontransformed or nontumorigenic breast
epithelial cells, rather than on the growth of breast carci-
noma cells. NAF and CAF have been reported to stimulate
the proliferation of normal human breast epithelial cells
[7,39] or to have no effect on the rate of proliferation of nor-
mal breast epithelial cells immortalized by SV40 large-T
antigen [8]. The overriding observations from these previ-
ous studies of fibroblast–epithelial interactions are that co-
cultured fibroblasts affect the growth of epithelial cells, but
this growth is dependent on the source of the fibroblasts,
the characteristics of the epithelial cells, and the culture
conditions utilized.
In a co-culture system similar to that presented here, NAF
(two different cultures) inhibited the growth, measured by
direct counting of total viable cells in co-cultures, of
MCF10A cells and MCF10AT-EIII8 cells – whereas CAF
induced the growth of both epithelial cell lines [22]. While
our findings for NAF are similar to the previous results, we
did not find a promotional effect of CAF on epithelial cell
growth. This discrepancy may be a result of the interindivid-
ual variation found in fibroblast cultures and/or differences
in epithelial cells (MCF10AT cells versus MCF10AT-EIII8
cells, an estrogen-induced derivative of the MCF10AT
cells). In addition, the total number of viable cells present
(fibroblasts and epithelial cells) in co-cultures were
counted, whereas in the current study only proliferation of
epithelial cells was measured. In the previous study, an E:F
ratio of 1:1 was utilized compared with the current E:F of
2:1. In support of the latter, we found that CAF at lower E:F
values of 1:1 and 1:2 no longer inhibited the growth of
MCF10A cells. Although not identical, this result is more in
keeping with that of Shekhar and colleagues [22].
Varying E:F ratios have been utilized in a few prior studies
of the effect of fibroblasts on the growth of breast
carcinoma cells. Ratios have varied from a great predomi-
nance of epithelial cells [9] to a predominance of fibrob-
lasts [7,14]. In these previous studies, an increasing
proportion of breast fibroblasts, either NAF or CAF, corre-
lates with an increase in growth of co-cultured cancerous
breast epithelial cells to a plateau where no further
enhancement of growth is seen. This is in general concord-
ance with our results, where the inhibitory effect of both
NAF and CAF on proliferation of MCF10A cells was less
with increasing numbers of fibroblasts, particularly for NAF.
This suggests the presence of fibroblast-derived factors
that both inhibit and promote the proliferation of epithelial
cells; at higher concentrations of fibroblasts, the promo-
tional effect predominates.
To be biologically relevant, the most meaningful ratio of epi-
thelial cells to fibroblasts depends on the lesion or tissue
being modeled. In the present study, the intent was to
model proliferative breast disease and DCIS, the putative
precursors of invasive carcinoma, which are believed to
have their origins in terminal ducts within terminal duct-lob-
ular units [41]. Microscopic examination of such intraductal
lesions in the human breast reveals a range of E:F, depend-
ing on the extent of fibrosis of the lesion. In the normal
terminal duct-lobular unit and in situ lesions depicted in Fig.
3, the E:F varies from 3:1 to 2:1. These ratios were deter-
mined by counting epithelial cells (both luminal and myoep-
ithelial cells) and stromal cells identified as fibroblasts and
located within or in close proximity to the terminal duct-lob-
ular unit involved. It is probable that those fibroblasts in
proximity to the epithelial structures have the greatest influ-
ence on epithelial cell behavior. Our choice to use an initialBreast Cancer Research    Vol 7 No 1    Sadlonova et al.
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E:F of 2:1 is therefore appropriate, whereas lower ratios
with many more fibroblasts are less common within terminal
duct-lobular units in vivo.
Prior attempts to identify fibroblast-derived factors that are
mediating the effect of NAF and CAF on breast epithelial
cell growth have identified IGF I and/or IGF II as partially
contributing to the mitogenic effect of fibroblasts [11]. Pre-
vious studies have reported that IGF II was expressed at a
moderate to high level in 43–57% of breast cancers by in
situ hybridization and by immunohistochemistry [17,42,43],
with localization primarily to stromal fibroblasts or vessel
walls [17,42], making IGF II a potential candidate to medi-
ate fibroblast–epithelial interactions. Additionally, in cul-
tures of CAF and NAF, IGF II mRNA was detected at higher
levels more frequently in CAF than in NAF in some studies
[33,44], but not in other studies [45,46].
In the current study, IGF II levels in fibroblasts were
assessed in both monolayer cultures and 3D cultures by
ELISA and quantitative real-time PCR. While more CAF
cultures than NAF cultures had relatively higher levels of
IGF II mRNA or protein, no significant differences in mean
quantities of IGF II mRNA or protein between these CAF
and NAF were observed. We also found no difference in
IGF II expression in the 3D co-cultures of MCF10AT cells
prepared with NAF versus CAF, suggesting that MCF10AT
cells do not alter IGF II expression to a different degree in
co-cultured NAF and CAF. Furthermore, we found no cor-
relation between proliferation of MCF10AT cells in co-cul-
ture and the level of IGF II protein in 3D fibroblast
monocultures or 3D co-cultures. Differences in IGF II
expression in NAF and CAF are therefore unlikely to explain
the difference in the effect of CAF versus that of NAF on
proliferation of the epithelial cells described in this study.
Our results do not eliminate a role for the IGF system in
these fibroblast–epithelial cell interactions as other family
members, such as IGF II receptor and a multitude of IGF
binding proteins, may be mediating these interactions in
other ways.
Prior studies by other workers [33,44-46] and the current
work underscore the variability in expression of IGF II and
in the growth inhibitory effect of NAF and CAF, and empha-
size the importance of including several NAF and CAF cul-
tures from different individuals in studies of fibroblast–
epithelial cell interactions. The interindividual heterogeneity
observed among NAF and CAF complicates assessment of
mechanisms underlying fibroblast–epithelial interactions.
Broad generalizations based on the results of experiments
using only one or two fibroblast cultures should be avoided.
In conclusion, both NAF and CAF have the ability to sup-
press breast epithelial cell proliferation; however, the
capacity of CAF to inhibit proliferation is less than that of
NAF. This suggests that there are differences in either
secreted factors or intercellular interactions between NAF
and CAF that render CAF less effective in inhibiting prolif-
eration, particularly of more transformed epithelial cells.
Furthermore, differences between the phenotypes of the H-
ras overexpressing MCF10AT cells and the parental
MCF10A cells cause MCF10AT cells to be more resistant
to the suppressive effect of fibroblasts. Future work to
identify the key fibroblast–epithelial interactions mediating
these effects may reveal mechanisms to allow restoration of
the inhibitory of effect of fibroblasts during the carcinogenic
process.
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